Research programme: anti-infectives - Abbott Laboratories/SelectX
Alternative Names: Anti-infectives research programme: Abbott Laboratories/SelectXLatest Information Update: 05 Oct 2004
At a glance
- Originator Ibis Therapeutics; SelectX Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 05 Oct 2004 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 27 Aug 2004 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
- 20 Sep 2002 OmniScience Pharmaceuticals has merged with BioChemist Inc. to form SelectX Pharmaceuticals